Catalyst Pharmaceuticals, Inc. (CPRX): Price and Financial Metrics

Catalyst Pharmaceuticals, Inc. (CPRX): $15.33

0.12 (-0.78%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

B

Add CPRX to Watchlist
Sign Up

CPRX Price/Volume Stats

Current price $15.33 52-week high $17.50
Prev. close $15.45 52-week low $11.48
Day low $15.17 Volume 648,300
Day high $15.50 Avg. volume 1,332,464
50-day MA $15.65 Dividend yield N/A
200-day MA $14.51 Market Cap 1.81B

CPRX Stock Price Chart Interactive Chart >


Catalyst Pharmaceuticals, Inc. (CPRX) Company Bio


Catalyst Pharmaceuticals focuses on the development and commercialization of prescription drugs targeting rare neurological diseases and disorders. The company was founded in 2002 and is based in Coral Gables, Florida.


CPRX Latest News Stream


Event/Time News Detail
Loading, please wait...

CPRX Latest Social Stream


Loading social stream, please wait...

View Full CPRX Social Stream

Latest CPRX News From Around the Web

Below are the latest news stories about CATALYST PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CPRX as an investment opportunity.

Small Caps Are On A Tear Including Speculative Biotechs

So far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation.

TalkMarkets.com | December 26, 2023

Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma

CORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its collaboration partner, DyDo Pharma, Inc. ("DyDo"), reported that it has submitted a New Drug Application (“NDA”) to Japan's Pharmaceuticals and Medical Devices Agency (“PMDA”) seeking marketing approval

Yahoo | December 18, 2023

7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar

With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks.

Josh Enomoto on InvestorPlace | December 17, 2023

Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 8, 2023

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies

Catalyst Ranked #4 on the ListCORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2024. Catalyst has ranked an impressive 4th out of 100 companies on this prestigious list, which recognizes small-cap companies that have demonstrated positive sales growth over the last twelve months. "We are very honored to b

Yahoo | December 5, 2023

Read More 'CPRX' Stories Here

CPRX Price Returns

1-mo -7.98%
3-mo -4.60%
6-mo 6.61%
1-year 23.93%
3-year 169.89%
5-year 303.42%
YTD -8.80%
2023 -9.62%
2022 174.74%
2021 102.69%
2020 -10.93%
2019 95.31%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!